Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101

The future of Editas Medicine’s EDIT-101 will be determined in November after a data readout from the Phase I/II BRILLIANCE study is available.

The data could inform the company whether there is a potential commercial path forward for the gene therapy. Editas will need to see a meaningful benefit in order for the program to move on to a registrational study, said Chief Executive Officer Gilmore O’Neill on Wednesday.